2026 Bioelectronic Medicine Forum

New York Academy of Medicine, New York, NY April 14, 2026

Keynote Speaker

Michel Maharbiz, Ph.D., CEO, iota Biosciences

Michel cofounded iota Biosciences in 2017. He is a serial entrepeneur and in his spare time loves bouldering, hiking, and off-roading. Until 2021, Michel was a full professor and is now an adjunct professor with the department of electrical engineering and computer science at the University of California, Berkeley. Prof. Maharbiz received his B.S. from Cornell University and his Ph.D. from the University of California, Berkeley under nanotechnologist Prof. Roger T. Howe and synthetic biologist Jay D. Keasling. He is a senior member of the IEEE Engineering in Medicine and Biology Society and a member of the Society for Neuroscience. Prof. Maharbiz is a recipient of the McKnight Foundation's Technological Innovations in Neuroscience Award, a Chan-Zuckerberg Biohub Investigator, a Bakar Fellow, and recipient of a National Science Foundation CAREER Award.

Conference Moderators

James Cavuoto, Editor and Publisher, Neurotech Reports

James Cavuoto is editor and publisher of Neurotech Business Report and BioElectRx Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," and "The Market for Bioelectronic Medicine," two market research reports published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).

Jeremy Koff, Senior Consulting Editor, Neurotech Reports

Mr. Koff is senior consulting editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.

Jo Jo Platt, Senior Contributing Editor, Neurotech Reports

Jo Jo Platt brings more than 10 years experience as a neurotechnology consulant to Neurotech Reports. As the founder and president of Platt & Associates, she has helped leadership identify new opportunities, transform organizations, and build teams from the ground up. Most recently, she was a strategic development consultant for the Feinstein Institute for Medical Research, where she helped identify and establish strategic partnerships in the emerging field of bioelectronic medicine and was instrumental in the launch of the Center for Bioelectronic Medicine. Previously, Jo Jo communications director for eDigital, where she managed all internal and external communications and built braand recognition through tradeshows and consumer events. Platt holds a bachelor's degree in communication and media studies from National University. She has served as the finance chair for the IEEE Engineering in Medicine and Biology Neural Engineering meeting.

Victor Pikov, Ph.D., Contributing Editor, BioElectRx Business Report

Victor Pikov is a contributing editor to Neurotech Report's new publication, BioElectRx Business Report and also co-founder and CEO of Medipace Inc, a startup developing implantable neuromodulation therapies for auto-immune intestinal diseases. Victor previously worked at Galvani Bioelectronics and GlaxoSmithKline, where he oversaw development and testing of implantable pulse generators and stimulation leads for several clinical applications, including auto-immune and metabolic diseases. At the Huntington Medical Research Institutes, Victor developed neural interfaces for various chronic diseases, such as infertility, bladder paralysis, bladder spasticity/hyperreflexia, hearing and vision loss, tinnitus, obstructive sleep apnea, and obesity. At the California Institute of Technology, Victor developed optogenetic viral vectors for neuronal stimulation. Victor has several patent applications for implantable neural interfaces, closed-loop neuromodulation therapies, and noninvasive glucose measurement.

Panelists and Presenters

Allan Gobbs, Managing Partner, ATEM Capital

Allan Gobbs is the Managing Partner at ATEM Capital, a New York-based Life Sciences venture firm. In recent years, Allan has seen five of his portfolio companies go public on NASDAQ, including notable names like Atea Pharmaceuticals, Marinus Pharmaceuticals, and Syndax Pharmaceuticals. Additionally, four of his portfolio companies have been successfully acquired, such as Tobira Therapeutics, which was bought by Allergan for up to $1.7 billion, and Amolyt Pharmaceuticals, AI-drug discovery peptide-based company acquired by AstraZeneca for up to $1.05 billion in July 2024. Allan is also the CEO and Chairman of YCare, a digital health integrator in strategic partnership with Dell Technologies and InterSystems, and the Chairman of PGxAI, an AI-powered pharmacogenetics platform. He serves as the President of Virry Health, an AI-powered XR platform focused on tackling mental health conditions, and is a Board Member of Heos Machines, a 3D bioprinting startup. Prior to joining ATEM Capital, Allan was an investment banker at Barclays Capital and other financial institutions, where he advised on mergers, acquisitions, and capital market transactions totaling over $20 billion. He is also a member of the Forbes Business Council, the Private Directors Association, and serves on the Review Committee of the National Cancer Institute at the NIH. 

Adam Rosenwach, CEO, Founding Managing Partner, Star51 Capital

Adam Rosenwach is the founding managing partner at Star51 Capital, a newsly formed venture investment vehicle designed to bridge the gap between innovation and acquisition. Anchored by a leading healthcare system and a top-tier global Medtech strategic, the fund focuses specifically on the convergence of Medtech and AI, leveraging deep industry ties to accelerate market entry and liquidity. Adam has been CFO for high-growth Medtech startups including Axon, Coridea, and Deerfield Catalyst. He is an expert in navigating complex financial structures and venture scaling. He is a graduate of Berklee College of Music, and obtained his MBA at Wharton.

Nandan Lad, M.D., Ph.D., Vice Chair of Innovation, Duke Neurosurgery

Nandan Lad, MD, PhD is a neurosurgeon, scientist, and innovator, serving as a Professor of Neurosurgery and Vice Chair of Innovation at Duke Neurosurgery. Dr. Lad leads the Duke Neuromodulation Program with the belief that multidisciplinary approaches are key to enhancing patient outcomes. Working with teams at the forefront of medtech and digital health innovation, Dr. Lad is committed to developing and utilizing cutting-edge technologies to treat pain, movement disorders, and a variety of complex neurological conditions. He believes in a blend of personalized care and advanced technological solutions, aiming to not only alleviate symptoms but also significantly improve quality of life and restore function for his patients.

Adam Caplan, Founder and General Partner, Jumpspace Ventures

Adam Caplan is the the founder of Jumpspace Ventures, a venture firm focused on breakthrough innovations in neuroscience and human-machine interfaces. With a portfolio of companies advancing brain-computer interfaces, neuromodulation, and neural diagnostics, Adam is passionate about technologies that record from or stimulate the brain and nervous system to treat serious conditions like motor neuron disease, epilepsy, and stroke. Prior to Jumpspace, Adam co-founded ID8 Investments (a diversified venture capital firm), Facteus (a leader in alternative data for financial markets), and Artisan Council (a digital marketing agency). Prior to being an entrepreneur, Adam was investment banker with Morgan Stanley. He now combines entrepreneurial and financial experience with deep conviction in the future of neurotech and human augmentation.

Jeff Chu, Co-Founder and Managing Partner, Features Capital

Jeff Chu is a Co-Founder and serves as a Managing Partner at Features Capital. He is a seasoned medical device developer and technologist. He is directly responsible for the creation and development of nascent technologies from ideation through transfer to manufacturing for early-stage and global medical device companies. Over 21 years as CTO and Partner of Simbex, he delivered multiple products to market based on a wide spectrum of technologies in both the medical device and consumer marketplaces, from bench to bedside. His deep experience in software, hardware, and algorithm development coupled with his biomechanical systems expertise helps realize innovative solutions that seamlessly integrate with the consumer. He has served as Principal Investigator on several federally funded research innovation programs from both the NIH and the Department of Defense in the areas of rehabilitation, blast, and impact biomechanics. He has been an active angel and LP investor. He is a Corporator of Mascoma Bank, a Founding Steering Committee Member of the MedTech Collaborative, and a Core Director for the Translational Rehab Engineering Advances and the New England Pediatric Device Consortium. His work has received national recognition from Time Magazine, Sybase, Edison Awards, and Computerworlds. Before Simbex, he worked as an advanced concepts consultant for several companies in the sporting goods industry and taught graduate courses in the areas of clinical biomechanics and computer modeling. He holds 8 patents, with 6 patents pending. He received his BS and MS in Biomechanics from the University of Massachusetts, Amherst

Esther Novosel, Ph.D., CEO, neuroloop GmbH

Esther is a healthcare people leader with a proven track record in several strategic and commercial roles across the medtech industry. Focused on delivering above-market performance and driving organization’s strategy and marketing. She was formerly vice president of projects, portfolio, and strategy at Biotronik. Esther received a Ph.D. in bioengineering and biomedical engineering from the University of Stuttgart.

Jeffrey Cohen, Managing Director, Ladenburg Thalmann

Mr. Cohen is responsible for equity research coverage of medical technology and healthcare services. He has 19 years of experience directly involved in the worldwide financial markets, of which he has spent the past 11 years directly involved with healthcare research and sales. Prior to joining Ladenburg Thalmann, he was a Senior Healthcare Research Analyst at C.K. Cooper & Company focusing upon the biotechnology, medical technology, and healthcare services segments. Mr. Cohen also served as a healthcare research analyst at Jesup & Lamont Inc., where he focused upon medical technology with sector specialization within Cardiology, Vascular, Orthopedics and Diabetes. Prior to equity research & sales, he spent seven years trading and managing fixed‐income and equity derivative products at Cantor Fitzgerald, Sanwa Securities and the American Stock Exchange. Mr. Cohen holds a B.S.E. in Systems Engineering from the University of Pennsylvania and an M.B.A. from the University of Miami. He has also served as an Adjunct Professor of Business & Management at Lynn University teaching Economics, Management, and International Business.

Jay Jiang, Ph.D., Co-founder and CTO, Spiro Medical, Inc.

Jay Jiang is the CTO of newly formed Spiro Medical Inc. He was previously CTO of Axonics Inc. before that firm's acquisition by Boston Scientific. Jiang is a seasoned technical executive and named inventor with more than 20 years of research and development experience in the medical device industry. He is a proven leader of cross-functional teams, successfully advancing innovative concepts from early development through commercial products. Jiang has extensive experience collaborating with academic and industry partners to create novel solutions addressing unmet medical needs. He received his Ph.D. in biomedical engineering from the University of Southern California  and a Masters degree in materials science and engineering from Michigan Tech.

Marom Bikson, Ph.D., Professor of Biomedical Engineering, City College of New York

Marom Bikson is a Cattell Professor of Biomedical Engineering at The City College of New York of the City University of New York and co-Director of the Neural Engineering Group at the New York Center for Biomedical Engineering. The translational R&D activity of his group spans pre-clinical studies, computational models, device design and fabrication, regulatory activities, and clinical trials. Technologies developed by his group are in clinical trials in over 100 medical centers and include neuromodulation interventions for neuropsychiatric disorders, intra- and post-operative sensors, patient compliance tools, and surgeon training simulators. Dr. Bikson has published over 200 papers and book chapters and is inventor on over 30 patent applications. He is known for his work on brain targeting with electrical stimulation, cellular physiology of electric effects, and electrical safety. Dr. Bikson co-invented High-Definition transcranial Direct Current Stimulation, the first noninvasive, targeted, and low-intensity neuromodulation technology. Dr. Bikson consults for medical technology companies and regulatory agencies on the design, validation, and certification of medical instrumentation. Prior to becoming faculty at CUNY, Dr. Bikson was a research fellow at the University of Birmingham Medical School, U.K. and a Research Associate at Sontra Medical LLC, in Cambridge, Massachuesetts. Dr. Bikson received his Ph.D. in Biomedical Engineering from Case Western Reserve University, in Cleveland, OH and a B.S. in Biomedical Engineering from Johns Hopkins University, Baltimore, MD.

Jennifer French, Executive Director, Neurotech Network

Jennifer French is the executive director and the founder of Neurotech Network, a nonprofit organization founded in Florida in 2003. Jennifer acquired her C6-7 incomplete spinal cord injury in 1998. Prior to her injury, she was recreationally active with such sports as canoeing, snowboarding/skiing, sailing, fly fishing, biking. After her injury, she still participates in all those activities. She is an active user of an FES system. Now residing in Tampa, FL, Jen is active in the community accessible sailing program, Sailing Alternatives as well as the national US Sailing, Sailors with Special Needs. French has helped launch successful divisions is such organizations as Bombardier Capital and PC Connection, Inc. With an MBA specializing in marketing & strategy, she works with for-profit and not-for-profit organizations, large and small, emerge into new markets, profile target customers and create and build systems to support sales efforts. She is the author of On My Feet Again (Neurotech Press, 2013), her personal story of rehabilitation using neurotechnology.

Entrepreneur Presenters

Ben Woodington, Ph.D., Co-Founder and CEO, Coherence Neuro

Ben is the co-founder and CEO of Coherence Neuro (formerly opto.bio) Coherence builds implantable neurotechnology for the treatment and monitoring of cancer. He completed his PhD training at The University of Cambridge under Prof George Malliaras and Damiano Barone where he worked on flexible, thin-film, and shape changing electronics to interface with the spinal cord and brain, with applications in spinal cord injury. Prior to that he worked on drug delivery device, at several large medtech companies, where his efforts spanned research, new product introduction, and academic partnerships.  

Stefan Kampusch, Ph.D., CEO, Aurimod GmbH

Stefan Kampusch achieved his BSc degree in Electrical Engineering and his MSc degree in Biomedical Engineering from the Faculty of Electrical Engineering at TU Wien, Austria, in 2010 and 2012, respectively. Since 2009 his research is focused on closed-loop electrical neuromodulation and auricular vagus nerve stimulation in chronic diseases. In 2015 he co-founded AURIMOD GmbH and currently serves as CEO and Head of R&D. AURIMOD has developed a wearable auricular vagus nerve stimulation system to help patients with chronic low back pain.

Mehmet Günal, Ph.D., CEO and Co-Founder, Brill Neurotech

Mehmet Günal is a neuroscientist, entrepreneur, and executive innovating at the intersection of brain-computer interfaces, noninvasive neuroimaging, and human-computer interaction. He brings over a decade of experience spanning cognitive neuroscience, digital signal processing, brain imaging, and neurotechnology development. As CEO and co-ounder of BRILL, Dr. Günal leads the development of next-generation noninvasive BCI technologies. BRILL is pioneering a new brain-imaging modality optimized for Fast Optical Signals, aiming to redefine real-time brain mapping with unprecedented temporal and spatial resolution. His work is laying the foundation for transformative applications in neuroscience research, clinical neurotechnology, and brain-computer interfaces. Previously, Dr. Günal served as a NIRS Research Application Scientist at ISS Medical, where he spearheaded research and development initiatives to advance functional near-infrared spectroscopy and FOS technologies. He led software and hardware innovation, translating cutting-edge scientific discoveries into practical brain imaging solutions, and trained researchers worldwide on best practices for neuroimaging and metabolic monitoring technologies. Dr. Günal’s research expertise was refined at the Cognitive Neuroimaging Lab at the University of Illinois Urbana-Champaign, where he specialized in non-invasive BCIs based on FOS, targeting motor control and attention through primary motor cortex and prefrontal cortex activity. Beyond BRILL, Dr. Günal founded AccessMyResearch, a nonprofit platform dedicated to democratizing academic knowledge by connecting academia, the public, and industry through free access to scholarly publications.

Amir Soltanianzadeh, CEO, StimCardio Medical

Amir Soltanianzadeh is a medtech executive, entrepreneur, and investor with a strong track record of building and scaling innovative medical device companies. He is the CEO of StimCardio Medical, which is developing the world’s first non-invasive therapy for Atrial Fibrillation through a wearable, closed-loop neuromodulation platform. Previously, Amir co-founded and served as CEO of Spine Align, where he led the development of novel 3D imaging and sensing technologies for complex spine navigation. The company was successfully acquired by a public orthopedic industry leader in 2021. Amir is also the Founder and Managing Partner of Solardis Health Ventures, investing in breakthrough medical device technologies across cardiovascular and digital health. He holds a B.S. in Biomedical Engineering from Boston University and an M.S.E. in Bioengineering Innovation & Design from Johns Hopkins University.